share_log

Hyperfine Analyst Ratings

Benzinga ·  Aug 15, 2023 10:55
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/15/2023 48.31% B. Riley Securities $2.5 → $3.5 Maintains Buy
03/22/2023 5.93% B. Riley Securities $3.5 → $2.5 Maintains Buy
10/04/2022 48.31% B. Riley Securities → $3.5 Initiates Coverage On → Buy
08/11/2022 1.69% Wells Fargo $8 → $2.4 Downgrades Overweight → Equal-Weight
05/31/2022 196.61% Evercore ISI Group → $7 Initiates Coverage On → Outperform
04/14/2022 238.98% Wells Fargo → $8 Initiates Coverage On → Overweight

What is the target price for Hyperfine (HYPR)?

The latest price target for Hyperfine (NASDAQ: HYPR) was reported by B. Riley Securities on August 15, 2023. The analyst firm set a price target for $3.50 expecting HYPR to rise to within 12 months (a possible 48.31% upside). 3 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Hyperfine (HYPR)?

The latest analyst rating for Hyperfine (NASDAQ: HYPR) was provided by B. Riley Securities, and Hyperfine maintained their buy rating.

When is the next analyst rating going to be posted or updated for Hyperfine (HYPR)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Hyperfine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Hyperfine was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

Is the Analyst Rating Hyperfine (HYPR) correct?

While ratings are subjective and will change, the latest Hyperfine (HYPR) rating was a maintained with a price target of $2.50 to $3.50. The current price Hyperfine (HYPR) is trading at is $2.36, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment